ReviewPharmacoEconomics1999
Counting the costs of drug-related adverse events.
Review in PharmacoEconomics, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pharmacogenetic Approach for the Prevention of Rivaroxaban's ADRs: A Systematic Review and Meta-Analysis.Genetics research · 2023Pooled it
- Pooled it
- A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting.Clinical interventions in aging · 2014Pooled it
- How are the costs of drug-related morbidity measured?: a systematic literature review.Drug safety · 2012Pooled it
- The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review.Drug safety · 2012Pooled it
- Revealing the Future of Pharmacovigilance in Precision Pharmaceutical Monitoring.Current drug safety · 2026Review
- Article
- A Systematic Review of Drug-Related InteractionsUtilizing Deep Learning and LLMs for Prediction and Mitigation.ACS omega · 2025Review
- The use of PD-1 functional knockout rats to study idiosyncratic adverse reactions to nevirapine.Toxicological sciences : an official journal of the Society of Toxicology · 2024Article
- Prevalence, Characteristics and Factors Associated with Adverse Drug Reactions Among Hospitalized Patients.Hospital pharmacy · 2024Article
- Development of Prediction Model Using Machine-Learning Algorithms for Nonsteroidal Anti-inflammatory Drug-Induced Gastric Ulcer in Osteoarthritis Patients: Retrospective Cohort Study of a Nationwide South Korean Cohort.Clinics in orthopedic surgery · 2023Article
- Article
- Under-reporting of adverse drug reactions: Surveillance system evaluation in Ho Municipality of the Volta Region, Ghana.PloS one · 2023Article
- Knowledge and Behavior in Rational Drug Use Among College Students in Zunyi City.Risk management and healthcare policy · 2022Article
- Incident adverse drug reactions and their effect on the length of hospital stay in older inpatients.International journal of clinical pharmacy · 2021Article
- Drug use pattern using WHO core drug use indicators in public health centers of Dessie, North-East Ethiopia.BMC medical informatics and decision making · 2021Article
- Multi-Drug Featurization and Deep Learning Improve Patient-Specific Predictions of Adverse Events.International journal of environmental research and public health · 2021Article
- Relationship Between the Gut Microbiome and Systemic Chemotherapy.Digestive diseases and sciences · 2020Review
- A Time-Embedding Network Models the Ontogeny of 23 Hepatic Drug Metabolizing Enzymes.Chemical research in toxicology · 2019Article
- Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.BMC pharmacology & toxicology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug events occur frequently and lead to a significant number of fatalities each year. It has been estimated that fatalities directly attributable to adverse drug reactions are the fourth to sixth leading cause of death in US hospitals, exceeding deaths caused by pneumonia and diabetes. The economic burden resulting from drug-related morbidity and mortality is equally significant and has been conservatively estimated at $US30 billion dollars annually, and could exceed $US130 billion in a worst-case scenario. Since many adverse drug events are considered preventable, increased efforts should be made to avoid classes of drugs that are problem-prone and to initiate diligent monitoring of drugs with predictable toxicities. Programmes should also be implemented that improve medication use practices within institutions. Although nearly all drugs are capable of producing an injury, certain drugs are more likely to do so. Prevention of drug-related morbidity and mortality has become an increasingly important requirement for reducing healthcare expenditures. This article will review studies that examine the economic implications of drug-related adverse events.
Indexed as
Identifiers
10537962What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.